Sonorous Neurovascular Receives FDA 510(k) Clearance for BosCATH™ Neurovascular Catheter

Key Takeaways

• FDA grants 510(k) clearance to Sonorous Neurovascular’s BosCATH™ next-generation neurovascular catheter
• Device designed to improve access and procedural efficiency in complex cerebral venous and arterial anatomies
• Clearance enables commercial launch of innovative catheter technology for neurovascular interventions

---

Sonorous Neurovascular announced April 22, 2026, that the U.S. Food and Drug Administration has granted 510(k) clearance for its BosCATH™ neurovascular catheter, marking a significant milestone for the Lake Forest, California-based medical device company.

The BosCATH™ represents a next-generation advancement in neurovascular catheter technology, specifically engineered to enhance access, delivery, and procedural efficiency during complex cerebral venous and arterial interventions. This FDA clearance positions Sonorous Neurovascular to commercialize its innovative solution for healthcare providers treating challenging neurovascular conditions.

Enhanced Neurovascular Access Technology

The newly cleared device addresses critical needs in neurovascular procedures, where precise catheter navigation through complex cerebral anatomy can significantly impact patient outcomes. The BosCATH™ catheter’s design focuses on improving physician ability to access difficult-to-reach areas within the brain’s vascular system.

Sonorous Neurovascular has positioned itself as a pioneer in cerebral venous disease solutions, developing technologies specifically for neurovascular interventions that require enhanced precision and reliability. The company’s focus on innovative medical devices addresses gaps in current treatment options for complex cerebrovascular conditions.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Market Impact and Commercial Implications

The 510(k) clearance enables Sonorous Neurovascular to begin commercial distribution of the BosCATH™ catheter in the United States. This regulatory milestone represents validation of the company’s engineering approach and clinical development strategy for neurovascular devices.

The neurovascular intervention market continues expanding as minimally invasive procedures gain adoption for treating stroke, aneurysms, and other cerebrovascular conditions. Advanced catheter technologies like the BosCATH™ support this trend by providing physicians with improved tools for complex procedures.

With FDA clearance secured, Sonorous Neurovascular can now focus on market introduction, physician training, and establishing distribution partnerships to bring this technology to healthcare facilities performing neurovascular interventions.

---

Frequently Asked Questions

What conditions will the BosCATH™ catheter treat?

The BosCATH™ catheter is designed for neurovascular interventions involving complex cerebral venous and arterial anatomies, supporting procedures for various cerebrovascular conditions requiring precise catheter access.

When will the BosCATH™ catheter be available to hospitals?

With FDA 510(k) clearance granted in April 2026, Sonorous Neurovascular can now begin commercial distribution, though specific availability timelines will depend on the company’s manufacturing and distribution rollout plans.

How does BosCATH™ improve upon existing neurovascular catheters?

The BosCATH™ is specifically designed to enhance access, delivery, and procedural efficiency in complex cerebral anatomies, though specific technical advantages over existing catheters would require detailed product specifications from the manufacturer.

Related coverage

• Shionogi's Xocova Gains FDA Clearance for COVID-19 Post-Exposure Prevention
• Nuance Pharma Secures IND Clearance for Actair® in China